Posts Tagged: CIRM
News
California’s $12 billion stem cell and gene therapy program could be treading water for the next 12 months in the view of at least one of its leaders as it searches for a new president of the 19-year-old enterprise. Past presidential searches have been burdened by a legal, dual executive arrangement that has been described by a former board member as a “dog’s breakfast.”
News
The neuro task force of the California Institute of Regenerative Medicine, chaired by CIRM Director Larry Goldstein, is scheduled to meet next Wednesday morning (October 18th) to discuss an overall funding approach for allocating $1.5 billion in research toward neuro diseases like brain cancer and epilepsy.
News
Directors of the $12 billion California stem cell agency will face a fundamental question next week that could determine whether its efforts to produce revolutionary treatments for afflictions ranging from heart disease to cancer will live or die.
News
It was a $24-million-a-minute meeting for California’s stem cell and gene therapy agency.
News
Nine California research organizations will vie behind closed doors this week as the state’s stem cell agency scores their bids to kick off what would be a first-in-the-nation, $80 million manufacturing network to speed the development of revolutionary medical therapies.
News
Come March 28, Vito Imbascani is scheduled to be sworn in as the new chairman of the $12 billion California stem cell agency – an 18-year-old state program to develop revolutionary treatments for such things as brain and blood cancers, heart disease, diabetes, sickle cell disease, spina bifida, incontinence, blindness, arthritis, HIV, stroke, epilepsy and much more.
News
Gov. Gavin Newsom has rebuked California’s stem cell agency about its conduct of the election of a new chairperson for the $12 billion enterprise, a process that has been disrupted with the withdrawal of one candidate and the addition of a new one.
News
Nearly three years after a British firm abandoned a successful therapy for the life-threatening “bubble baby” disease, children will again be treated in a clinical trial backed with millions of dollars from the state of California. “It’s the best Christmas gift ever,” said the mother of an afflicted child, Andrea Fernandez.
News
California has another election coming up this fall, but it is not your usual political campaign free-for-all. Instead, it involves the leadership of the $12 billion state stem cell agency, which is trying mightily to develop “miraculous” treatments and cures for diseases that afflict — according to its backers — half of the families in California.
News
It was a $137 million day for the Golden State’s stem cell agency — no small event even for an enterprise that is backed by billions. The scientific scope covered by the $137 million was impressive. It ranged from bolstering the vaunted Alpha Clinic Network initiated around the state by the California Institute for Regenerative Medicine (CIRM), as the agency is legally known, to raising the number of CIRM’s clinical trials to 83.
The Sue and Bill Gross Stem Cell Research building at University of California Irvine, a CIRM major facility. Photo courtesy of CIRM
